Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate‐to‐severe chronic plaque psoriasis: A comparative study

Ranjan, Nitin; Sharma, Nand Lal; Shanker, Vinay; Mahajan, Vikram K.; Tegta, Geeta Ram

doi:10.1080/09546630701499291

Cited by 34 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[59] Gach et al [60] used hydroxyurea in combination with infliximab to treat a recalcitrant case of psoriasis.…”

Section: Hydroxyureamentioning

confidence: 98%

Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics?

Kanwar¹,

Yadav²,

Dogra³

2010

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Psoriasis is a common debilitating disease significantly affecting the quality of life of the patients. Majority of the psoriasis patients have mild disease which can be managed by topical therapies. Around 30% of the psoriasis patients require systemic therapy during the course of their disease. There is a vast array of drugs for the treatment. Methotrexate, cyclosporine and retinoids are the most commonly used conventional systemic drugs. Newer studies provide insight into their more effective and safer use and as combination therapy with biologics. In recent times, many new drugs with novel mechanisms of action other than biologics have been tried in psoriasis. In this article, we have reviewed the current developments and new found role of the conventional drugs as well as the newer nonbiologic systemic drugs in the treatment of psoriasis.

show abstract

“…[59] Gach et al [60] used hydroxyurea in combination with infliximab to treat a recalcitrant case of psoriasis.…”

Section: Hydroxyureamentioning

confidence: 98%

Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics?

Kanwar¹,

Yadav²,

Dogra³

2010

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

show abstract

“…Most patients display at least mild hematologic abnormalities, especially an asymptomatic macrocytic anemia, and up to one third require dose adjustment. 161 Liver and renal toxicity is rare. Some patients may experience skin pigmentation or diffuse alopecia; but these effects are typically dose dependent and reversible with discontinuation.…”

Section: Hydroxyureamentioning

confidence: 98%

“…Methotrexate treatment (at 15-20 mg/wk) led to a 77% reduction in the mean PASI score whereas hydroxyurea treatment (at the lower dose of 3-4.5 g/wk) led to a 49% reduction in the mean PASI score. 161 The major adverse effect of hydroxyurea is bonemarrow toxicity causing leukopenia, anemia, thrombocytopenia, or, less commonly, pancytopenia. Most patients display at least mild hematologic abnormalities, especially an asymptomatic macrocytic anemia, and up to one third require dose adjustment.…”

Section: Hydroxyureamentioning

confidence: 99%

Guidelines of care for the management of psoriasis and psoriatic arthritis

Menter¹,

Korman²,

Elmets³

et al. 2009

Journal of the American Academy of Dermatology

488

161

View full text Add to dashboard Cite

“…Overall, the data suggest hydroxyurea is inferior to methotrexate at achieving PASI 75 over a 3-month term. 40 However, hydroxyurea may be more effective when used for a longer duration (9-16 months). 41 Due to risk of bone marrow suppression, hydroxyurea has similar monitoring requirements to other antimetabolites and is contraindicated in pregnancy, nursing, or significant bone marrow suppression.…”

Section: Hydroxyureamentioning

confidence: 99%